Impact of ultra-low tidal volume ventilation on 1-year functional outcome in COVID-19 ARDS patients. A long-term follow-up analysis of a randomized controlled trial.
Summary
In this multicenter randomized trial follow-up (VT4COVID), ultra-low tidal volume ventilation did not improve 1-year mortality compared to standard low tidal volume in COVID-19 ARDS. ULTV was associated with a small but significant decline in cognitive status at day 365, potentially linked to higher PaCO2 exposure.
Key Findings
- 215 patients randomized to ULTV (n=106) vs LTV (n=109) across 10 ICUs.
- No significant difference in day-365 mortality (46% vs 42%).
- ULTV associated with a small but significant decrease in cognitive status at day 365.
- Trial prospectively registered (NCT04349618); open-label, multicenter design.
Clinical Implications
For COVID-19 ARDS, routine ultra-low tidal volumes beyond standard low tidal volume strategies should be reconsidered given no 1-year survival advantage and possible cognitive harm associated with higher permissive hypercapnia.
Why It Matters
Provides high-quality randomized evidence on the long-term trade-offs of pushing tidal volumes ultra-low, highlighting potential neurocognitive costs without survival benefit.
Limitations
- Open-label design with missing outcome data in some survivors.
- Trial conducted during the pandemic period; care variations may limit generalizability.
Future Directions
Define PaCO2 targets balancing lung protection and neurocognitive outcomes; assess ULTV in non-COVID ARDS and with neuroprotective strategies.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized controlled trial with prospective registration and long-term follow-up.
- Study Design
- OTHER